pragma.vision Your technology observatory

Verification register Bio, Health & Neuro

Readiness verdict

Illumina Connected Multiomics (ICM) with TruPath Genome

A dated reading of what is claimed, reported, and independently verified in the current evidence.

As of
2026-06-28
Revision
1
Method
v1.0.0

Current reading

The readiness gap, in one scan

AI-assisted assembly · derived results

Claimed
82

Public ambition and stated capability

Reported
81

Observed practitioner reporting

Verified
75

Independently supported evidence

Gap
+7

Claimed minus verified

Evidence strength Strong

Decision

What the current evidence supports

Human editorial judgment · 2026-06-28

Proceed with caution

Why
Strong, vendor-documented performance numbers (SV recall 51.5%->87.8%, ~98% SNV phasing, $395/genome) and real early-access adoption (Broad Clinical Labs, GeneDx, Baylor), but short-read fundamentals, NovaSeq X lock-in, sample-quality sensitivity, and an incomplete TruPath<->ICM integration story warrant validation before reliance.
Next
Validate TruPath's SV recall and phasing on representative samples (meeting the 70% >10 kb / 40% >60 kb input guidance) against an established long-read baseline, and scope whether Connected Multiomics (research-only) meets the analysis use-case before building workflows on the 'connected' promise.

Constraints

Blockers

No named blocker is present in the current public projection.

Evidence summary

Derived counts

AI-assisted assembly

Total
7
Tier 1
0
Tier 2
0
Tier 3
7
Supports
4
Contradicts
1
Context
2
Latest observed
2026-02-24

Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.

Publication record

Revisions

Initial public reading

This is the initial public reading. No earlier readiness change is recorded.

Your opinion

Tell us anything.

What works, what doesn't, what's missing — especially about our watches, lenses, and the register itself. Anonymous is fine; leave an email if you'd like a reply.